# Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

> **NCT02519270** · PHASE1 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 62 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** IGN002

## Key facts

- **NCT ID:** NCT02519270
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-01
- **Primary completion:** 2018-05-04
- **Final completion:** 2018-05-04
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** Strategic Reasons
- **Last updated:** 2022-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02519270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02519270, "Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02519270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*